Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6

Journal of Clinical Pharmacology

Volumn 46, Issue 12, 2006, Pages 1426-1438

  Walsky, Robert L ^a   Astuccio, Angela V ^a   Obach, R Scott ^a  

^a PFIZER INC   (United States)

Author keywords

Drug drug interactions; HPLC MS MS; In vitro; P450 2B6; rhCYP2B6

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALENDRONIC ACID; ALLOPURINOL; ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; AMLODIPINE; AMOXICILLIN; AMPHETAMINE; ANASTROZOLE; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; AZITHROMYCIN; BENAZEPRIL; CLOPIDOGREL; CLOTRIMAZOLE; CYTOCHROME P450 2B6; EFAVIRENZ; ITRACONAZOLE; OXYGENASE; PARACETAMOL; PROPOFOL; RALOXIFENE; SALBUTAMOL; SELEGILINE; SERTRALINE; TICLOPIDINE; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; NONHUMAN;

ALGORITHMS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BUPROPION; CLOTRIMAZOLE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ITRACONAZOLE; KINETICS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXAZINES; PLATELET AGGREGATION INHIBITORS; RALOXIFENE; REVERSE TRANSCRIPTASE INHIBITORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TICLOPIDINE; XENOBIOTICS;

EID: 33750711672     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293753     Document Type: Article

References (41)

1. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77:553-559.
2. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005;45:68-78.
3. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos. 2004;32:626-631.
4. Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Development of a comprehensive panel of antibodies against the major xenobiotic metabolizing forms of cytochrome P450 in humans. Biochem Pharmacol. 1998;56:377-387.
5. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Expt Ther. 1994;270:414-423.
6. Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev. 1999;31:719-754.
7. Stresser DM, Kupfer, D. Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos. 1999;27:517-525.
8. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TKH, Waxman DJ. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos. 1997;25:985-993.
9. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003;43:149-173.
10. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacol. 2003;45:122-132.
11. Lamba V, Lamba L, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Expt Ther. 2003;307:906-922.
12. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genom. 2006;16;191-198.
13. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2005;61:148-154.
14. Faucette SR, Wang H, Hamilton GA, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004;32:348-358.
15. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29:413-580.
16. Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis. 2006;42:408-410.
17. Hanna IH, Reed JR, Guengerich P, Hollenberg PF. Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys. 2000;376:206-216.
18. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000;28:1222-1230.
19. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28:1176-1183.
20. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999;27:655-666.
21. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Expt Ther. 2003;306:287-300.
22. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853-858.
23. Crettol S, Deglon J-J, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78:593-604.
24. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004;76:250-269.
25. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001;94:110-119.
26. Hidestrand M, Oscarson M, Salonen JS, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. 2001;29:1480-1484.
27. Salonen JS, Nyman L, Boobis AR, et al. Comparative studies on the cytochrome P450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003;31:1093-1102.
28. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33:262-270.
29. Richter T, Murdter TE, Heinkele G, et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Expt Ther. 2004;308:189-197.
30. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004;32:647-660.
31. Kanamitsu S-I, Ito K, Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res. 2000;17:336-343.
32. Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple CYP involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos. 2005;33:837-844.
33. Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm. 1973;1:553-567.
34. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Expt Ther. 2006;316:336-348.
35. Sustiva®: (efavirenz) label. Princeton, NJ: Bristol-Myers Squibb Company; April 2005.
36. Ching MS, Blake CL, Ghabrial H, et al. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem Pharmacol. 1995;50:833-837.
37. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig, A. Absorption, metabolism, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Circulation. 2005;112:2946-2950.
38. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
39. Lewis DFV. Quantitative structure-activity relationships (QSARs) for substrates of human cytochrome P450 CYP2 family enzymes. Toxicol In Vitro. 2004;18:89-97.
40. Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001:1924-2023.
41. PDR® Electronic Library, Thomson MICROMEDEX. Greenwood Village, Colo; 2006.